119种药品新纳入医保
China adds 119 drugs to list
国家医疗保障局12月28日召开新闻发布会表示，有119种药品新纳入2020年国家医保目录，其中包括谈判调入的96种独家药品和16种今年新上市的药品。这些药品的价格大幅降低，惠及更多群众。
China has included 119 more kinds of drugs on its national medical insurance reimbursement list, delivering greater price cuts and benefiting more people, the National Healthcare Security Administration (NHSA) said at a press conference Monday. Ninety-six of the new additions to the list are exclusive drugs that offer lower prices through negotiation and 16 were newly put on the market this year, the NHSA said.
共计有162种药品进行了谈判，为历史最多的一次。
Altogether, a record number of 162 drugs on the list were negotiated for price reduction.
最终有119种药品谈判成功，谈判成功的药品平均降价50.64%。
A deal was reached for 119 of the drugs, with their prices dropping an average of 50.64 percent.
此次药品目录调整也有助于扩大报销范围，覆盖了新冠肺炎等多种疾病的用药。
The inclusions also helped expand the scope of reimbursement to cover more diseases, including COVID-19.
国家医疗保障局表示，最新版国家新冠肺炎诊疗方案所列药品已被全部纳入。
So far, all the medicines listed in China's latest diagnosis and treatment plan for COVID-19 have been added to the reimbursement list, the NHSA said.
通过本次目录调整，国家医保目录内的药品总数为2800种，其中中成药1374种。
China currently has 2,800 kinds of medicines on the medical reimbursement list, including 1,374 traditional Chinese patent medicines.